Business Context and Reporting Period
Company: CareCloud, Inc. (CCLD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: CareCloud is a leading provider of technology-enabled revenue cycle management (RCM) and cloud-based healthcare IT solutions. The company serves approximately 45,000 providers across 2,900 practices and hospitals in 50 states. Its business model leverages a cost-effective offshore workforce (primarily in Pakistan and Sri Lanka) to deliver services at competitive prices. The company operates two segments: Healthcare IT and Medical Practice Management.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Revenue | $120.5 million | $110.8 million |
| GAAP Net Income | $10.8 million | $7.9 million |
| Net Income Attributable to Common Shareholders | $3.9 million | $(4.5 million) |
| Adjusted EBITDA | $27.5 million | $24.1 million |
| Adjusted Operating Margin | 12.2% | 10.3% |
| Cash and Restricted Cash (Year End) | $3.6 million | $5.1 million |
| Working Capital | $1.3 million | $5.2 million |
| Total Liabilities | $28.1 million | $21.8 million |
| Preferred Stock Dividends Paid | $6.3 million | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 9% year-over-year, driven primarily by the acquisition of Medsphere Systems Corporation (contributing ~$10.5 million in revenue) and organic growth in professional services.
- Profitability: GAAP net income increased 37% to $10.8 million. Adjusted EBITDA grew 15% to $27.5 million. The company returned to profitability attributable to common shareholders ($3.9 million) after a loss in 2024, largely due to the conversion of Series A Preferred Stock which reduced dividend obligations.
- Acquisitions: The company completed three significant acquisitions in 2025: Medsphere ($16.5 million purchase price), MAP App ($0.6 million), and RevNu ($0.6 million). These added significant goodwill ($12.3 million) and intangible assets.
- Capital Structure: In March 2025, the company converted the majority of its Series A Preferred Stock into common stock. This reduced the monthly cash dividend obligation on preferred stock from approximately $1.1 million to $455,000.
- Dividend Status: After suspending preferred dividends in December 2023, the company resumed payments in February 2025. As of December 31, 2025, approximately $6.8 million in preferred dividends remained in arrears.
Guidance, Outlook, and Risks
Management Commentary & Strategy: Management is focused on reducing costs, maintaining profitability, and generating positive free cash flow to satisfy preferred stock dividend arrears. The strategy involves leveraging offshore operations for cost advantages, expanding AI capabilities (CareCloud cirrusAI), and continuing an acquisition strategy to consolidate the fragmented RCM market.
Outlook: The company plans to pay double monthly dividends on Series B Preferred Stock starting February 2026 to reduce the arrearage. No cash dividends are anticipated for common stockholders in the foreseeable future.
Key Risks:
- Offshore Operations: Significant reliance on operations in Pakistan and Sri Lanka exposes the company to political instability, sanctions, and infrastructure risks.
- Liquidity & Dividends: The ability to pay preferred dividends is contingent on compliance with loan covenants (specifically with Provident Bank) and sufficient cash flow. Failure to meet covenants could prohibit dividend payments.
- Cybersecurity: As a custodian of sensitive patient data, the company faces risks from cyberattacks, data breaches, and evolving regulatory requirements (HIPAA, HITECH).
- Acquisition Integration: Risks associated with integrating acquired businesses (Medsphere, MAP App, RevNu) and retaining their customers.
Investor Verification Checklist
- Dividend Arrears: Verify the current status of the $6.8 million in preferred dividends in arrears and the company's ability to fund the proposed "double dividend" payments starting in 2026.
- Debt Covenants: Review the specific financial covenants in the Provident Bank credit agreement (e.g., debt service coverage ratio) to assess the risk of default restricting dividend payments.
- Offshore Concentration: Assess the concentration of expenses and operations in Pakistan and Sri Lanka and the potential impact of geopolitical events or sanctions on the cost structure.
- Acquisition Synergies: Monitor the integration progress of the Medsphere acquisition to ensure projected revenue and cost savings are realized.
- Goodwill Impairment: Given the significant increase in goodwill ($12.3 million added in 2025), monitor future impairment testing, especially if stock price or market conditions deteriorate.